AxoGen, Inc (AXGN) SVP Sells $434,700.00 in Stock

AxoGen, Inc (NASDAQ:AXGN) SVP Shawn F. Mccarrey sold 10,000 shares of the stock in a transaction on Wednesday, May 16th. The stock was sold at an average price of $43.47, for a total value of $434,700.00. Following the transaction, the senior vice president now owns 33,057 shares of the company’s stock, valued at $1,436,987.79. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Shares of AxoGen stock opened at $43.95 on Monday. AxoGen, Inc has a 12 month low of $13.95 and a 12 month high of $46.00. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.32 and a quick ratio of 2.81.

AxoGen (NASDAQ:AXGN) last announced its earnings results on Monday, April 30th. The medical equipment provider reported ($0.11) EPS for the quarter, meeting analysts’ consensus estimates of ($0.11). AxoGen had a negative return on equity of 61.66% and a negative net margin of 18.83%. The company had revenue of $17.30 million during the quarter, compared to analysts’ expectations of $17.16 million. AxoGen’s revenue for the quarter was up 41.8% compared to the same quarter last year. equities analysts expect that AxoGen, Inc will post -0.38 EPS for the current year.

Institutional investors have recently made changes to their positions in the stock. Ladenburg Thalmann Financial Services Inc. boosted its holdings in AxoGen by 41.6% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,575 shares of the medical equipment provider’s stock valued at $167,000 after acquiring an additional 1,345 shares during the period. Princeton Capital Management LLC purchased a new position in AxoGen during the 1st quarter valued at about $183,000. Paloma Partners Management Co purchased a new position in AxoGen during the 4th quarter valued at about $215,000. Guggenheim Capital LLC purchased a new position in AxoGen during the 4th quarter valued at about $228,000. Finally, Gotham Asset Management LLC purchased a new position in AxoGen during the 4th quarter valued at about $249,000. Institutional investors own 71.02% of the company’s stock.

A number of research firms have recently weighed in on AXGN. ValuEngine upgraded AxoGen from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target (up from $37.00) on shares of AxoGen in a report on Tuesday, May 1st. JMP Securities increased their price target on AxoGen from $34.00 to $43.00 and gave the stock a “market outperform” rating in a report on Tuesday, May 1st. Lake Street Capital set a $38.00 price target on AxoGen and gave the stock a “buy” rating in a report on Friday, March 2nd. Finally, William Blair began coverage on AxoGen in a report on Monday, February 5th. They set an “outperform” rating for the company. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. AxoGen presently has a consensus rating of “Buy” and a consensus target price of $35.57.

AxoGen Company Profile

AxoGen, Inc develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Insider Buying and Selling by Quarter for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply